Take a look at our previous reports:

Q3 2022 operational review

Jyseleca commercial & regulatory progress

  • Strong adoption across Europe with reimbursement for rheumatoid arthritis (RA) in 15 countries and for ulcerative colitis (UC) in 10 countries
  • Marketing Authorization Application (MAA) submitted for the treatment of UC to Swissmedic, the regulatory authority in Switzerland
  • Article 20 pharmacovigilance procedure ongoing by the European Medicines Agency (EMA)

Pipeline update

  • Preparations advanced to start Phase 2 of GLPG3667 (TYK2 inhibitor) in dermatomyositis, with the aim to recruit the first patients around year-end

Corporate update

  • Received various transparency notifications from FMR LLC, indicating that its shareholding in Galapagos changed, without crossing below the 5% threshold, to 5.65% of the current outstanding Galapagos shares
  • Raised €6.7 million year-to-date through the exercise of subscription rights
Dermatomyositis is a rare inflammatory disease. Common symptoms include distinctive skin rash, and inflammatory myopathy, or inflamed muscles, causing muscle weakness
European Medicines Agency, in charge of European market authorization of new medications
A TYK2 kinase inhibitor discovered by us, topline results from the Phase 1b in psoriasis reported in July 2021